HER2-low breast tumors were characterized by a higher frequency of hormone positive and PIK3CA mutations, a lower frequency of TP53 mutations, and the pCR rate of neoadjuvant therapy when compared to HER2-zero tumors [25]. This evidence concerns the gene PIK3CA and breast neoplasm.